The Research Unit at Hospital Pharmacy Funen, Odense University Hospital, was established in 2016 and currently counts ten researchers. Deprescribing constitutes one of our main research areas, with a specific focus on deprescribing at the end of life, while we also do research related to transitions of care and clinical research. Read more about the research unit here.
The unit is represented by professor and Head of Research Anton Pottegård, who has published more than 200 peer-reviewed papers on use of medications.
The Research Unit at Department of Geriatric Medicine, Odense University Hospital and University of Southern Denmark, is an expanding entity both in terms of affiliated researchers and scientific output. Its main research areas comprise clinical pharmacy and frailty among older patients as well as cross sectional research. Read more about the research unit here.
The unit is represented by professor, consultant, and Head of Research Jesper Ryg, who has published more than 50 peer-reviewed papers within the multiple aspects of geriatric medicine including use of medications, frailty, and end-of-life matters.
Clinical Pharmacology and Pharmacy, University of Southern Denmark embraces all aspects of drug research with a primary focus on clinical pharmacology (translational- and clinical research) as well as housing an internationally recognized pharmacoepidemiology unit. The research unit currently counts four professors, three associate professors, and >30 post docs, PhD students and support staff. Read more about it here.
The unit is represented by associate professor Daniel Pilsgaard Henriksen, who has published more than 60 peer-reviewed papers, mainly regarding adverse effects of drug treatment, and who manages a virtual polypharmacy outpatient clinic.
The research Unit for General Practice, Department of Public Health, University of Southern Denmark embraces all aspects of primary care research including clinical trials, epidemiology, organisational research, implementation methods and research on chronic diseases. The research unit currently counts seven professors, fourteen associate professors, and >40 post docs, PhD students and support staff.
The unit is represented by professor Jens Søndergaard, MD, PhD, general practitioner, clinical pharmacologist, research leader of the Research Unit of General Practice. He has published more than 250 peer-reviewed papers.
A portfolio of projects including literature reviews, qualitative studies and quantitative studies to describe patient’s, relatives’ and health care professionals’ barriers regarding deprescribing.
For older individuals reaching the last years of life, continued use of some medications may be of questionable benefit due a limited life expectancy and shifts in goals of care. In such situations, it may therefore be relevant to reduce or discontinue treatment with these medications. Despite this, a number of barriers towards deprescribing have been identified among both patients, relatives, and health care professionals.
In a series of papers, we explore attitudes towards deprescribing from the perspective of both patients, relatives, and health care professionals. We do this to get a better understanding of what may hinder as well as facilitate deprescribing, as this will help us developing interventions, tools, and strategies that may improve the uptake of deprescribing in clinical practice. We explore patient/relative and prescriber perspectives through both systematic reviews, qualitative studies, and surveys.
A primary care RCT testing a comprehensive deprescribing intervention on quality of life among patients with limited life expectancy.
Numerous deprescribing interventions have been shown to be feasible, safe, and generally effective at reducing medication use. However, the evidence of impact on patient-important outcomes, such as quality of life, is limited.
With ODIN-1, we will test whether a comprehensive and patient-centered deprescribing intervention can improve quality of life as well as other outcomes among older patients with limited life expectancy. The intervention will be focused on aligning medical treatment with patient’s preferences, and it will be carried out in collaboration between patient and general practitioner.
The trial will be initiated during the summer of 2020 and run for one year. The study is funded by the VELUX Foundation.
An RCT testing two interventions to stop treatment with proton pump inhibitors among patients without an indication for continued treatment.
The use of proton pump inhibitors is extensive, also among patients without indication for treatment. Deprescribing.org have developed and made available tools to deprescribe proton pump inhibitors. In this project, we will test two such tools.
Patients will be recruited at community pharmacies when redeeming a proton pump inhibitor. Eligible patients, i.e. those with no ongoing indication for treatment, will be randomized 1:1 to a simple intervention or an extended intervention. The simple intervention will provide patients with a pamphlet on PPI deprescribing. The extended intervention is the patient pamphlet and an individual telephone consultation with a pharmacist where a collaborative plan for PPI deprescribing is developed.
The trial will be completed during 2020 and it is funded by the Region of Southern Denmark and Regionernes Medicinpulje.